Dr José Baselga Wiki
Dr José Baselga Biography
Memorial Sloan Kettering Cancer Center paid its chief physician Jose Baselga $ 1.5 million in severance pay after he resigned under fire for failing to disclose payments of millions of dollars from pharmaceutical and healthcare companies on a dozen research papers that he wrote.
Dr. José Baselga resigned from Memorial Sloan Kettering in the context of the controversy in 2018.
The non-profit organization Baselga paid more than $ 1.5 million
Recent IRS filings show nonprofit Baselga paid more than $ 1.5 million in severance payments in 2018 and 2019, according to the New York Times.
The hospital declined to comment on whether Baselga had received additional redundancy pay in 2020.
A spokesperson told the outlet that the above payments were part of the hospital’s “contractual obligation” under Baselga’s employment contract, but declined to elaborate.
Baselga is now an executive at the pharmaceutical company AstraZeneca, where he oversees the development of its cancer drugs. He also declined to comment.
Charities often enter into employment contracts with senior officials who provide compensation upon their departure. These agreements can be difficult to break, except in cases where a court has determined that something is illegal.
However, the law requires institutions to disclose the nature of their severance pay arrangements for senior officials in their IRS records.
Baselga’s departure in fall 2018 is said to have shaken Sloan Kettering, where he was serving as medical director.
Baselga was considered one of the best breast cancer doctors in the world at the time and did not disclose millions of dollars in payments from pharmaceutical and healthcare companies. In doing so, financial ties were removed from dozens of research articles written in publications such as the New England Journal of Medicine.
He has also served on the board or advisory positions at several other companies, including Roche, was involved in startups testing cancer therapies, and played a key role in developing innovative drugs that revolutionized breast cancer treatment, The Times and ProPublica reported.
In a 2017 article, he positively evaluated the results of two Roche clinical studies that many found disappointing, without revealing his ties to the company.
The Times reported that it had received $ 3 million in consulting fees from Roche in the previous four years.
Baselga said at the time that his failure to disclose relationships with Roche and at least a dozen companies was unintentional.
“I admit there have been inconsistencies, but it is,” he told the Times. “It’s not that I don’t appreciate the importance.”
Baselga’s disclosures resulted in a review of Memorial Sloan Kettering’s relationship with the pharmaceutical and healthcare industries, as well as significant changes to its conflict of interest policy.
Memorial Sloan Kettering CEO Dr. Craig B. Thompson apologized to his staff for handling the Baselga exit in the fall of 2018, telling staff: “The events of the last few weeks have not been about the way I would have liked. ”
Then-chairman of the board, Douglas A. Warner III, meanwhile, admonished Baselga, saying his “lines crossed” and “ready to go” when dealing with for-profit companies, the Times reported.
As Baselga officially left office, Warner suggested that the departure was not voluntary, saying: “He left us no choice.”
Baselga, a leading researcher, confirmed his mistakes in a resignation letter, saying that the controversy surrounding him had been “too distracting,” ultimately leading to his decision to resign.
The doctor also resigned from the boards of the drugmaker Bristol-Myers Squibb and Varian Medical Systems, a manufacturer of radiation protection equipment, and the Cancer Journal, where he was editor.
Senior executives at Memorial Sloane Kettering can no longer serve on boards of directors of pharmaceutical and healthcare companies. Limitations have also been placed on how executives and top researchers can benefit from the work done at the facility.
Hospital finances have reportedly been hit hard by the pandemic. A loss of $ 453 million was recorded in the first three quarters of 2020. During the same period in 2019, the hospital had a profit of $ 77 million.